Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis Manfred Ballmann, Horst von der Hardt

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

Use of the insulin pump in treat cystic fibrosis related diabetes Dana S. Hardin, Julie Rice, Mark Rice, Randall Rosenblatt Journal of Cystic Fibrosis.

Volume 46, Issue 3, Pages (March 2007)

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis Michael W. Konstan, Felix Ratjen

Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation Helge Hebestreit, Annette Sauer-Heilborn, Rainald Fischer,

Cost of care and clinical condition in paediatric cystic fibrosis patients Ulrich Baumann, Christiane Stocklossa, Wolfgang Greiner, Johann-Matthias Graf.

Achromobacter species in cystic fibrosis: Cross-infection caused by indirect patient-to- patient contact C.R. Hansen, T. Pressler, W. Ridderberg, H.K.

Dorene F. Balmer, Joan I. Schall, Virginia A. Stallings

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Use of high-dose ibuprofen in a pediatric cystic fibrosis center

R. Roberts, L. Speight, J. Lee, L. George, R. I. Ketchell, D. Lau, J

A. Mirakhur, M.J. Gallagher, M.J. Ledson, C.A. Hart, M.J. Walshaw

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

H. Grasemann, E. Tullis, F. Ratjen Journal of Cystic Fibrosis

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation Kris De Boeck, Anne Munck, Seth Walker, Albert Faro,

Ludger Dorlöchter, Malin Carlsson, Edda J. Olafsdottir, Ola D

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Adults with cystic fibrosis prefer hypertonic saline before or during airway clearance techniques: a randomised crossover trial Ruth L. Dentice, Mark.

Cirrhosis and other liver disease in cystic fibrosis

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Pulmonary exacerbations in CF patients with early lung disease

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF Christina Schjellerup Dalbøge, Tacjana.

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Controlled clinical trials in cystic fibrosis — are we doing better?

Adherence to nebulised therapies in adolescents with cystic fibrosis is best on week- days during school term-time Rosemary Ball, Kevin W. Southern, Pamela.

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state Bradley.

The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation Verena I. Seliger, David Rodman, Fredrick Van.

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Effect of supervised training on FEV1 in cystic fibrosis: A randomised controlled trial Susi Kriemler, Stephanie Kieser, Sibylle Junge, Manfred Ballmann,

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Cystic fibrosis related diabetes in an extremely young patient

Physiologic endpoints for clinical studies for cystic fibrosis

Characterisation of mutations and genotype–phenotype correlation in cystic fibrosis: Experience from India Shivaram S. Shastri, Madhulika Kabra, Sushil.

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

Correlation of sweat chloride and percent predicted FEV1 in cystic fibrosis patients treated with ivacaftor Meredith C. Fidler, Jack Beusmans, Paul Panorchan,

Valerie Waters, Eshetu G

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United.

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

C. Van de Kerkhove, P. C. Goeminne, M. Kicinski, T. S. Nawrot, N

D Peckham, A Watson, K Pollard, C Etherington, S.P Conway

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Randomized, single blind, controlled trial of inhaled glutathione vs placebo in patients with cystic fibrosis C. Calabrese, A. Tosco, P. Abete, V. Carnovale,

DNase in stable cystic fibrosis infants: a pilot study

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study E.M. Westerman, P.P.H.

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis Malena Cohen-Cymberknoh, Hannah Blau, David Shoseyov,

Predictors of non-referral of patients with cystic fibrosisfor lung transplant evaluation in the United States Kathleen J. Ramos, Bradley S. Quon, Kevin.

Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis

Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Does the timing of inhaled dornase alfa matter?

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis Ahmet Z. Uluer, David A. Waltz, Leslie.

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial Michael W. Konstan, Patrick A. Flume, Matthias.

Cystic fibrosis and pregnancy in the modern era: A case control study

Safety assessment of inhaled xylitol in subjects with cystic fibrosis

H. White, A.M. Morton, D.G. Peckham, S.P. Conway

Presentation transcript:

Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis Manfred Ballmann, Horst von der Hardt Journal of Cystic Fibrosis Volume 1, Issue 1, Pages 35-37 (March 2002) DOI: 10.1016/S1569-1993(01)00009-1

Fig. 1 Changes of FEV1(% predicted) from baseline are shown after 3 weeks treatment with HS (■) and with rhDNase (□) for each single patient. Patient no. 8 showed no change with HS. Journal of Cystic Fibrosis 2002 1, 35-37DOI: (10.1016/S1569-1993(01)00009-1)